Media headlines about Impax Laboratories (NASDAQ:IPXL) have trended positive on Wednesday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Impax Laboratories earned a media sentiment score of 0.32 on Accern’s scale. Accern also assigned news headlines about the specialty pharmaceutical company an impact score of 45.7189911556179 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Amneal Gains FDA Approval for Erythromycin Tablets USP (IPXL) (streetinsider.com)
- Amneal Gains Approval for Erythromycin Tablets USP (finance.yahoo.com)
- $0.17 Earnings Per Share Expected for Impax Laboratories Inc (IPXL) This Quarter (americanbankingnews.com)
- Impax faces U.S. antitrust trial over generic acne drug’s delay (finance.yahoo.com)
- Impax broke U.S. antitrust law by delaying generic drug, jury told (finance.yahoo.com)
IPXL has been the topic of a number of recent analyst reports. Cantor Fitzgerald set a $35.00 price objective on Impax Laboratories and gave the company a “buy” rating in a research note on Friday, December 15th. SunTrust Banks initiated coverage on Impax Laboratories in a report on Wednesday, March 7th. They issued a “buy” rating and a $24.00 target price on the stock. BidaskClub raised Impax Laboratories from a “sell” rating to a “hold” rating in a report on Thursday, February 8th. Canaccord Genuity set a $19.00 target price on Impax Laboratories and gave the company a “hold” rating in a report on Thursday, February 22nd. Finally, Zacks Investment Research raised Impax Laboratories from a “strong sell” rating to a “hold” rating in a report on Monday, January 15th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. Impax Laboratories currently has an average rating of “Hold” and a consensus price target of $20.91.
Shares of Impax Laboratories (NASDAQ IPXL) traded down $0.20 during mid-day trading on Wednesday, reaching $20.55. The company had a trading volume of 1,176,864 shares, compared to its average volume of 1,008,937. The company has a current ratio of 1.96, a quick ratio of 1.52 and a debt-to-equity ratio of 4.11. The firm has a market cap of $1,489.82, a price-to-earnings ratio of -3.15, a price-to-earnings-growth ratio of 0.86 and a beta of 1.01. Impax Laboratories has a twelve month low of $8.80 and a twelve month high of $25.70.
Impax Laboratories (NASDAQ:IPXL) last announced its quarterly earnings results on Thursday, March 1st. The specialty pharmaceutical company reported $0.11 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.12 by ($0.01). The company had revenue of $182.90 million during the quarter, compared to analyst estimates of $199.13 million. Impax Laboratories had a negative net margin of 60.49% and a positive return on equity of 10.42%. Impax Laboratories’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.16 EPS. research analysts anticipate that Impax Laboratories will post 1.27 EPS for the current year.
Impax Laboratories Company Profile
Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.
Receive News & Ratings for Impax Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.